The Role of GenAI Across the Clinical Trial Landscape

Generative AI holds immense promise in expediting drug discovery, optimizing patient selection criteria, and personalizing treatment approaches. By leveraging AI's ability to rapidly analyze vast datasets and identify complex patterns, researchers can uncover novel biomarkers, predict treatment responses, and stratify patient populations with unprecedented accuracy. Furthermore, GenAI facilitates more efficient trial design, enabling adaptive protocols and real-time monitoring to enhance trial efficacy and accelerate time-to-market for innovative therapies.

Despite the many potential applications, the adoption of gen AI in clinical trials is hindered by challenges such as regulatory clearance, biases, ethical considerations, and data privacy, among others. Furthermore, several companies operating in this space have created generative AI models, with applications for specific aspects of the clinical trials process, however, the value of these applications have yet to be proven for most use cases. 

Join this roundtable to discuss the current and future potential applications of gen AI across the clinical trials landscape, specifically: 

• What are the most noteworthy current applications of GenAI technologies for clinical trials, and what, if any, is the proven value of these applications? What will it take to have GenAI technologies applied across the entire clinical trial landscape? 

• What are the key considerations and potential challenges associated with implementing GenAI technologies in clinical trial settings, particularly regarding data privacy, regulatory compliance, and ensuring transparency and interpretability of AI-driven insights?

• In what ways can healthcare stakeholders collaborate to overcome challenges related to data interoperability, standardization, and regulatory compliance in implementing GenAI across the clinical trial landscape? How might partnerships between academia, industry, and regulatory agencies accelerate the adoption and integration of these innovative technologies?